Biotech Distilled

Substack ↗ Subscribe

Subscribe Substack ↗ About

Research Areas Modalities Phases Targets Track record Movers The Lead Compound

Home › Targets › CD8+ T cells

CD8+ T cells (1 companies · 1 programs)

Companies with an active program directed at CD8+ T cells.

SAB Biotherapeutics, Inc. SABS

SAB-142 — Type 1 Diabetes Phase 2

Track record About Feedback Report a bug Substack ↗

This website is an encyclopedia of clinical-stage biotech companies, refreshed weekly. For informational and educational use only — not investment advice. Always verify against primary sources before making decisions.